Canada markets closed

Cingulate Inc. (CINGW)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.0182-0.0017 (-8.54%)
At close: 04:00PM EDT

Cingulate Inc.

1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Laurie A. Myers M.B.A., Ph.D.Executive VP & COO415.17kN/A1957
Dr. Matthew N. Brams M.D.Executive VP & Chief Medical Officer244.79kN/A1964
Dr. Raul R. Silva M.D.Executive VP & Chief Science OfficerN/AN/A1958
Thomas DaltonVice President of Investor & Public RelationsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Corporate Governance

Cingulate Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.